Hansa Biopharma Receives the Esteemed 2025 SwedenBIO Award for Exceptional Achievements

Hansa Biopharma: Celebrating the 2025 SwedenBIO Award

Hansa Biopharma AB, known simply as Hansa, has recently achieved a significant milestone by winning the prestigious 2025 SwedenBIO Award. Announced during the SwedenBIO Summit held on January 21 in Stockholm, Hansa was recognized among numerous nominees for its outstanding contributions to the field of biotechnology and medicine. This accolade is given to companies that exemplify scientific excellence, operational success, and a meaningful international impact.

Since its inception in 2007, the SwedenBIO Award has aimed to honor businesses that have made significant strides in advancing scientific knowledge and health solutions. Hansa's recognition is particularly noteworthy as it symbolizes the transformation of Swedish scientific achievements into tangible global medical outcomes. Additionally, the award celebrates the company's leadership role in enhancing commercial capabilities on the international stage.

Hansa Biopharma has pioneered an innovative enzyme technology designed to facilitate life-saving transplantations for patients who are highly sensitized and have encountered historically unmet medical needs. The company’s flagship product, imlifidase, is a groundbreaking immunoglobulin G (IgG) antibody-cleaving enzyme therapy. This therapy has been instrumental in promoting kidney transplants in patients with heightened sensitivities, establishing Hansa as a key player in transplant medicine.

Moreover, the company aims to further its innovative agenda through strong clinical results and an unwavering commitment to research and development. Renée Aguiar-Lucander, CEO of Hansa Biopharma, expressed her heartfelt gratitude upon receiving the award. She remarked, "I am truly delighted and deeply honored to receive this award on behalf of everyone at Hansa Biopharma. This recognition reflects the great momentum we've built heading into 2026—powered by our strong U.S. Phase 3 data, the upcoming FDA review process, and the anticipated Phase 3 readout from our European Phase 3 trial later this year. Thank you to the SwedenBIO organization and judges for this recognition. We're proud of how far we've come, and excited for the journey ahead."

Hansa's commitment to addressing serious unmet medical needs extends beyond kidney transplantation. The company is also looking forward to advancing HNSA-5487, a next-generation IgG-cleaving molecule targeted for the treatment of Guillain-Barré Syndrome (GBS). By embracing pioneering innovations and consistently delivering remarkable clinical outcomes, Hansa Biopharma is reinforcing Sweden’s stature as a leader in life science advancements.

In summary, the receipt of the 2025 SwedenBIO Award is not just a testament to Hansa Biopharma's robust presence in the biotech landscape; it signals the company's dedication to transforming patient care through its innovative therapies. As they look to the future, Hansa Biopharma stands poised to continue making significant strides in providing life-changing solutions for patients worldwide. Their ongoing efforts reflect an enduring commitment to enhancing global health care and advancing scientific discovery.